Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKesson
AstraZeneca
Dow
Mallinckrodt

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for AG-120


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug AG-120?

AG-120 is an investigational drug.

There have been 23 clinical trials for AG-120. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Cancer Institute (NCI), and Institut de Recherches Internationales Servier.

There are twenty US patents protecting this investigational drug and two hundred and forty-one international patents.

Recent Clinical Trials for AG-120
TitleSponsorPhase
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionNational Cancer Institute (NCI)Phase 1
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionM.D. Anderson Cancer CenterPhase 1
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationNational Cancer Institute (NCI)Phase 1

See all AG-120 clinical trials

Clinical Trial Summary for AG-120

Top disease conditions for AG-120
Top clinical trial sponsors for AG-120

See all AG-120 clinical trials

US Patents for AG-120

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-120 ⤷  Sign up for a Free Trial Methods of treatment of malignancies Celgene Corporation (Summit, NJ) Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign up for a Free Trial
AG-120 ⤷  Sign up for a Free Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign up for a Free Trial
AG-120 ⤷  Sign up for a Free Trial Methods of treatment of malignancies Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign up for a Free Trial
AG-120 ⤷  Sign up for a Free Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Sign up for a Free Trial
AG-120 ⤷  Sign up for a Free Trial Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) ⤷  Sign up for a Free Trial
AG-120 ⤷  Sign up for a Free Trial Pharmaceutical compositions of therapeutically active compounds Agios Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-120

Drugname Country Document Number Estimated Expiration Related US Patent
AG-120 Australia AU2016393869 2036-02-26 ⤷  Sign up for a Free Trial
AG-120 Australia AU2016393870 2036-02-26 ⤷  Sign up for a Free Trial
AG-120 Canada CA3015753 2036-02-26 ⤷  Sign up for a Free Trial
AG-120 Canada CA3015757 2036-02-26 ⤷  Sign up for a Free Trial
AG-120 China CN109069410 2036-02-26 ⤷  Sign up for a Free Trial
AG-120 European Patent Office EP3419593 2036-02-26 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKesson
AstraZeneca
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.